<DOC>
	<DOCNO>NCT02005211</DOCNO>
	<brief_summary>This study consist two part , ie , single dose part young healthy subject ( Part 1 ) single multiple dose part elderly healthy subject ( Part 2 ) , assess safety , tolerability , pharmacokinetics pharmacodynamics AZD3293 follow single multiple ascend dose administration healthy subject .</brief_summary>
	<brief_title>A Two-part Single Multiple Dose Study Assess Safety , Pharmacokinetics Effects AZD3293 Healthy Japanese Young Elderly Volunteers</brief_title>
	<detailed_description>This Phase I , randomise , double-blind , placebo-controlled , single centre study ass safety , tolerability , pharmacokinetics pharmacodynamics AZD3293 follow single multiple ascend dose administration healthy subject . This study consist two part , ie , single dose part young healthy subject ( Part 1 ) single multiple dose part elderly healthy subject ( Part 2 ) . The study design allow gradual escalation dosage level sequential cohort safety monitoring ensure safety healthy subject .</detailed_description>
	<criteria>Healthy Japanese elderly young male female ( nonchildbearing potential ) Body mass index ( BMI ) 17 27 kg/m2 weigh least 40 kg 100 kg Psychiatric disease/condition , GI , renal , hepatic , cardiovascular , psychiatric , retinal disease disorder Use antipsychotic drug , chronic use antidepressant anxiolytic drug . Frequent use ( 2 day per week last 12 week ) tobacco nicotine product . Neurological disease , include seizure , recent memory impairment , clinically significant head injury .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>AZD3293</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Young volunteer</keyword>
	<keyword>Elderly volunteer</keyword>
	<keyword>Japanese volunteer</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Single multiple ascend dose study</keyword>
</DOC>